These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

143 related items for PubMed ID: 2138906

  • 1. Monoclonal antibodies that discriminate between human ovarian carcinomas and benign ovarian tumours.
    Boerman OC, Makkink WK, Thomas CM, Hanselaar AG, Yedema CA, Kenemans P, Poels LG.
    Eur J Cancer; 1990 Feb; 26(2):117-27. PubMed ID: 2138906
    [Abstract] [Full Text] [Related]

  • 2. Monoclonal antibody against human ovarian tumor-associated antigens.
    Poels LG, Peters D, van Megen Y, Vooijs GP, Verheyen RN, Willemen A, van Niekerk CC, Jap PH, Mungyer G, Kenemans P.
    J Natl Cancer Inst; 1986 May; 76(5):781-91. PubMed ID: 3517452
    [Abstract] [Full Text] [Related]

  • 3. Monoclonal antibodies against ovarian carcinoma-associated antigens, raised by immunization with cyst fluids.
    Boerman O, Makkink K, Massuger L, Thomas C, Kenemans P, Hanselaar T, Poels L.
    Anticancer Res; 1989 May; 9(3):551-8. PubMed ID: 2764501
    [Abstract] [Full Text] [Related]

  • 4. Comparative immunohistochemical study of four monoclonal antibodies directed against ovarian carcinoma-associated antigens.
    Boerman OC, van Niekerk CC, Makkink K, Hanselaar TG, Kenemans P, Poels LG.
    Int J Gynecol Pathol; 1991 May; 10(1):15-25. PubMed ID: 2007534
    [Abstract] [Full Text] [Related]

  • 5. Immunocytochemical detection of ovarian carcinoma cells in serous effusions.
    Cuijpers VM, Boerman OC, Salet van de Pol MR, Vooijs GP, Poels LG, Ramaekers FC.
    Acta Cytol; 1993 May; 37(3):272-9. PubMed ID: 8498129
    [Abstract] [Full Text] [Related]

  • 6. Comparative in vitro binding characteristics and biodistribution in tumor-bearing athymic mice of anti-ovarian carcinoma monoclonal antibodies.
    Boerman O, Massuger L, Makkink K, Thomas C, Kenemans P, Poels L.
    Anticancer Res; 1990 May; 10(5A):1289-95. PubMed ID: 2241105
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF, Pinedo HM, Schlüper HM, Nijman HW, Boven E.
    Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
    [Abstract] [Full Text] [Related]

  • 9. Relation between ovarian carcinoma-associated antigens in tumor tissue and detached cyst fluid cells of patients with ovarian neoplasms.
    Bar JK, Harłozińska A, Sobańska E, Cislo M.
    Tumori; 1994 Feb 28; 80(1):50-5. PubMed ID: 8191599
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Marker profile of different phases in the transition of normal human ovarian epithelium to ovarian carcinomas.
    van Niekerk CC, Boerman OC, Ramaekers FC, Poels LG.
    Am J Pathol; 1991 Feb 28; 138(2):455-63. PubMed ID: 1992770
    [Abstract] [Full Text] [Related]

  • 12. Immunotherapy in a human ovarian cancer xenograft model with two bispecific monoclonal antibodies: OV-TL 3/CD3 and OC/TR.
    van Ravenswaay Claasen HH, Eggermont AM, Nooyen YA, Warnaar SO, Fieuren GJ.
    Gynecol Oncol; 1994 Feb 28; 52(2):199-206. PubMed ID: 8314139
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Marker profile of mesothelial cells versus ovarian carcinoma cells.
    van Niekerk CC, Jap PH, Thomas CM, Smeets DF, Ramaekers FC, Poels LG.
    Int J Cancer; 1989 Jun 15; 43(6):1065-71. PubMed ID: 2659540
    [Abstract] [Full Text] [Related]

  • 15. Mouse monoclonal antibodies to human epithelial differentiation antigens expressed on the surface of ovarian carcinoma ascites cells.
    Mattes MJ, Look K, Furukawa K, Pierce VK, Old LJ, Lewis JL, Lloyd KO.
    Cancer Res; 1987 Dec 15; 47(24 Pt 1):6741-50. PubMed ID: 3677104
    [Abstract] [Full Text] [Related]

  • 16. Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients.
    Tibben JG, Thomas CM, Massuger LF, Segers MF, Schijf CP, Corstens FH, Boerman OC.
    Nucl Med Commun; 1995 Oct 15; 16(10):853-9. PubMed ID: 8570116
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vivo targeting of OV-TL 3 immunoliposomes to ascitic ovarian carcinoma cells (OVCAR-3) in athymic nude mice.
    Nässander UK, Steerenberg PA, Poppe H, Storm G, Poels LG, De Jong WH, Crommelin DJ.
    Cancer Res; 1992 Feb 01; 52(3):646-53. PubMed ID: 1732053
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.